n n n ‘. concat(e. i18n. t(“search. voice. recognition_retry”),’n
The market extension for immunofluorescence assays will increase from $3. 45 billion in 2023 to $5. 62 billion in 10 years. The increasing emergence of persistent fitness situations will drive the expansion of the immunofluorescence market.
Newark, March 14, 2024 (GLOBE NEWSWIRE) — Brainy Insights estimates that the immunofluorescence testing market, estimated at $3. 45 billion, will reach $5. 62 billion by 2033. There are lucrative expanding customers in emerging markets. Players will be located in emerging markets such as Brazil, China, and India in the coming years. This is mainly attributed to the diversity of fitness landscapes in those countries, as well as a notable prevalence of infectious and chronic diseases, an increase in spending on physical care, and an increase in studies and development projects by organizations. In particular, China and India have a high prevalence of diabetes, further highlighting the prospects for market expansion in those regions.
Get a PDF brochure of patterns: https://www. thebrainyinsights. com/enquiry/pattern-request/14097
Market Size of Immunofluorescence Testing Through Product (Reagent, Antibodies, Instruments, Kits, Consumables, and Accessories), Type (Direct, Indirect), End-User (in Pharmaceutical and Biotechnology Companies, Academic and Research Institutes,
Hospitals and Diagnostic Centers, Contract Research Organizations), Diseases (Infectious Diseases, Other Diseases), Regions, Global Industry Analysis, Share, Growth, Trends and Forecast 2024-2033 In 2023, North America dominated the immunofluorescence with a profit percentage of 41. 11%, driven through major industry players, healthcare infrastructure and government projects such as “Ending the Immunofluorescence Outbreak in the Industry”. HIV Program in US Asia-Pacific is expected to witness the fastest expansion (CAGR of 5. 76% from 2023 to 2030), driven by emerging economies, including India and China, which are fighting infectious diseases such as HIV and tuberculosis through supported projects. through organizations like the CDC.
Antibody dominated the market with 39. 13% of the total market.
The antibody sector dominated the market with 39. 13% of the overall market. This dominance is attributed to the basic role that antibodies play in immunofluorescence, where they label express target antigen fluorescent dye kits and the reagent segment is expected to succeed in the highest annual compound. expansion rate (CAGR) of 6. 96% during the projection period. This expansion is driven by the easy-to-use, cost-effective, and highly express nature of immunofluorescence kits.
Infectious diseases accounted for the largest market share at 59. 71% in 2023.
In 2023, the infectious diseases segment accounted for a significant profit percentage of 59. 71%, basically due to the widespread adoption of immunofluorescence techniques, especially for the diagnosis of COVID-19. The outbreak of the COVID-19 pandemic and increased awareness around early detection have been critical points contributing to the dominance of the segment. In contrast, autoimmune diseases, included in the other diseases segment, are expected to grow at the fastest compound annual expansion rate (CAGR) of 6. 57% from 2023 to 2030. Immunofluorescence testing plays a role in the diagnosis of autoimmune diseases. diseases through the detection of autoantibodies, especially in situations such as rheumatoid arthritis, lupus and multiple sclerosis, which are driving the expected expansion of this segment.
The pharmaceutical industry and biotechnology will dominate the market in 2023.
The Pharmaceutical and Biotechnology Corporations segment dominated the immunofluorescence market with a market share of 45. 49% in 2023, and an immediate expansion is expected from 2024 to 2030. These industry players drive expansion through strategic moves such as mergers, acquisitions, product development, approvals, and launches. and global operational expansion. It is also expected to be the fastest-growing segment in the world.
Oblique immunofluorescence will dominate the market in 2023.
In 2023, the oblique immunofluorescence segment ruled with a profit percentage of 65. 18% and is expected to grow at an immediate CAGR of 5. 65%. This technique, which uses number one and secondary antibodies, is more complex but provides greater sensitivity through a unique fluorochrome. Labeled technique for detecting antigen-antibody interactions. Their programs range from diagnosing diseases such as amebiasis to discovering autoantibodies in autoimmune diseases. The segment’s expansion is driven by cost-effectiveness, signal amplification, flexibility, and the benefits of high-tech. Quality images.
For more information on the analysis of this report, please contact the Research Analyst at https://www. thebrainyinsights. com/report/immunofluorescent-assay-market-14097
Latest development:
• In January 2023, Agilent and Akoya joined forces to create multiple chromogenic and immunofluorescent assays, integrating space research for biopharmaceutical corporations running precision cancer treatments. These dosing responses allow researchers and healthcare professionals to meet patients’ diverse needs for cutting-edge treatments and temporarily translate their effects into clinical trials.
• In June 2023, EUROIMMUN, under Revvity, introduced UNIQO 160, a state-of-the-art automated formulation for oblique immunofluorescence testing (IIFT) in the diagnosis of autoimmune diseases. This complex assay enhances the overall power of the entire IIFT process, which encompasses pattern preparation, incubation, slide washing, assembly, symbol acquisition, and analysis.
• In December 2023, First Light Diagnostics obtained FDA approval for its SensiTox B toxin control. Anthracis, an immunofluorescence assay that detects the first anthrax biomarkers by inhalation. The 20-minute monitoring, compatible with the MultiPath analyzer, for immediate and early diagnosis of anthrax infection. Federal investment by the U. S. Department of Health and Human ServicesThe U. S. Department of Homeland Security supported the progress of this test and the MultiPath analyzer. First Light’s SensiTox C. difficile toxin test is also authorized for the U. S. market. U. S.
Interested in getting the data? Find out more about: https://www. thebrainyinsights. com/enquiry/buying-inquiry/14097
Market Dynamics
Factors: Increased occurrence of persistent fitness conditions.
The increasing emergence of chronic and infectious diseases, coupled with rheumatoid arthritis, cancer, and HIV/AIDS, is poised for the immunofluorescence testing market for the foreseeable future. In addition, the expansion of investments in R
Retention: high expenditure on instruments
In immunofluorescence assays, complicated imaging tools play a critical role in the observation and localization of fluorescently labeled antibodies in a sample. The main advantage of those imaging tools comes from their incorporation of complex features and functionality. Growing Popularity of More Effective Alternative Tests: The immunofluorescence market is hampered by the growing preference for more effective choice tests. This trend toward diagnostic strategies of choice reflects a broader shift in the healthcare industry toward innovation and optimization.
Opportunity: Lucrative Expansion in Emerging Markets
Expected expansion customers for market players are in emerging markets such as Brazil, China, and India in the coming years. This is basically attributed to the diversity of fitness landscapes in those countries, as well as a notable prevalence of infectious and chronic diseases, an increase in spending on physical care, and an increase in studies and growth projects of organizations. Notably, China and India have a high prevalence of diabetes, further highlighting the prospects for market expansion in those regions.
Challenge: Shortage of experts
A major challenge that could obstruct the expansion of the immunofluorescence testing market is the shortage of professional experts. Immunofluorescence testing requires a professional workforce; However, the shortage of professionals poses a significant risk to the immunofluorescence market.
Some of the major players operating in the immunofluorescence market are:
• Thermo Fisher Scientific • Abcam plc • Bio-Rad Laboratories • PerkinElmer • Merck KgaA • Werfen • Cell Signaling Technology • MEDIPAN GmbH • Sino Biological • Danaher Corporation
The key market segments:
By product:
• Reagent • Antibodies • Instruments • Kits • Consumables & Accessories
By Type:
• Direct Indirect
By End User:
• Pharmaceutical and biotechnology corporations • Academics and institutes • Hospitals and diagnostic centers • Contractual organizations
By Type:
• Infectious • Other
Purchase a copy of the report for a single user: https://www. thebrainyinsights. com/buy-now/14097/unmarried
About the report:
The global immunoflorescence testing market is analyzed on the basis of its price (in billions of USD). All segments were analyzed at the global, regional, and national levels. The review includes research from more than 30 countries per party. The report offers in-depth research of the drivers, opportunities, constraints, and demanding situations to get a critical review of the market. The exam includes the Carrier Five Forces Model, Attractiveness Analysis, Raw Material Analysis, Supply Analysis, Demand Analysis, Competitor Position Grid Analysis, Distribution Channel Analysis, and Merchandising.
About Brainy Insights:
Brainy Insights is a market research company whose purpose is to provide businesses with actionable insights through knowledge analysis for their business vision. We have a physically powerful forecasting and estimating style to meet traditional high-quality production purposes in a short period of time. . We provide traditional (client-specific) reporting and syndication reporting. Our syndication report repository varies across categories and subcategories across all domains. Our tradition-driven responses are designed to meet the demands of traditionalists, whether they’re looking to expand or are making plans to launch a new product in the global marketplace.
Contact us
Avinash Business Development Representative Phone: 1-315-215-1633 Email: sales@thebrainyinsights. com Web: http://www. thebrainyinsights. com